Table II.
Multivariate Cox proportional hazard regression analysis of patient demographic and clinical characteristics and survival.
| PFS | OS | |||
|---|---|---|---|---|
| Variable | HR (95% CI) | P-value | HR (95% CI) | P-value |
| ECOG-PS, 2 | 1.032 (0.783–1.231) | 0.462 | 0.923 (0.872–1.253) | 0.188 |
| TNM stage, IV | 1.059 (0.718–1.629) | 0.521 | 0.936 (0.783–1.258) | 0.894 |
| Post/pre CD4+CD25+CD127+ T lymphocytes >0.6 | 1.574 (1.381–2.932) | 0.017 | 1.859 (1.136–2.264) | 0.006 |
| Post/pre CD8+CD28+ T lymphocytes ≤2.2 | 1.834 (1.524–3.187) | 0.011 | 2.732 (1.774–5.673) | 0.002 |
| Infusion cycles | 1.103 (0.851–1.253) | 0.724 | 0.972 (0.761–1.354) | 0.758 |
| DC-CIK combined with CT | 0.436 (0.168–0.579) | 0.001 | 0.343 (0.257–0.857) | 0.035 |
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; TNM, Tumor-Node-Metastasis; DC-CIK, dendritic cells-cytokine-induced killer cells; CT, chemotherapy.